U.S. FDA cuts gap for Moderna COVID-19 booster dose to 5 months

U.S. FDA cuts gap for Moderna COVID-19 booster dose as cases surge The U.S. Food and Drug Administration on Friday shortened the interval between the primary series of Moderna Inc's COVID-19 vaccine and a booster dose to five months, as it looks to bolster protection against the fast-spreading Omicron variant. Reuters Reuters

Jan 7 (Reuters) - The U.S. Food and Drug Administration on Friday shortened the interval between the primary series of Moderna Inc's (MRNA.O) COVID-19 vaccine and a booster dose to five months, as it looks to bolster protection against the fast-spreading Omicron variant.

The agency expects the shorter interval, reduced by a month for people aged 18 and above, will provide better protection sooner against the variant, which is driving up infections and overwhelming hospitals. read more  ...

The FDA earlier this week cut the interval to get a booster dose of Pfizer (PFE.N) and BioNTech COVID-19 vaccine, based on mRNA technology like Moderna's, to five months from six. read more

"Vaccination is our best defense against COVID-19, including the circulating variants, and shortening the length of time between completion of primary series and a booster dose may help reduce waning immunity," Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said.

People who received Johnson & Johnson's (JNJ.N) single-dose COVID-19 vaccine can get a booster dose two months later.